Mankind Pharma Ltd.

NSE: MANKIND · Healthcare

₹2,540.00+0.87%06 Nov 2026

Ask the data

Instant answers about Mankind Pharma Ltd. — computed from its filings, no language model

Market cap₹1,04,902 cr

Current price₹2,540.00

High / Low₹2,618 / ₹1,927

P/E46.7

P/B5.97

Book value₹425.7

ROE12.8%

ROCE14.6%

Debt / equity0.31

Dividend yield0.04%

EPS (TTM)₹54.45

Face value₹1

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

	FY23	FY24	FY25	FY26
Revenue	8,749	10,335	12,207	14,278
EBITDA	1,901	2,535	3,018	3,617
Operating margin	21.7%	24.5%	24.7%	25.3%
Interest	44	34	429	639
Depreciation	326	398	621	886
Profit before tax	1,659	2,384	2,504	2,321
Tax	362	458	510	395
Net profit	1,282	1,913	1,986	1,913
EPS ₹	32.00	47.75	49.28	46.35
Operating cash flow	1,813	2,152	2,413	3,121
Capex	832	382	520	737
Dividend paid	0	0	0	41
Total assets	9,715	11,963	27,760	28,080
Equity	7,435	9,363	14,332	16,300

Quarterly performance

last 15 quarters · ₹ crore

showing latest 8 of 15 periods

	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25*	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
Revenue	2,053	2,579	2,708	2,607	2,441	2,893	3,077	3,230	-151	3,570	3,697	3,567	3,443	4,031	4,338
Operating profit	417	655	683	607	591	682	850	830	-147	847	921	919	930	1,056	1,171
Operating margin	20.3%	25.4%	25.2%	23.3%	24.2%	23.6%	27.6%	25.7%	97.3%	23.7%	24.9%	25.8%	27.0%	26.2%	27.0%
Other income	48	59	60	70	92	101	109	77	174	80	92	73	114	45	95
Interest	5	6	9	9	9	11	7	221	-30	171	170	157	142	110	105
Depreciation	85	87	96	110	105	108	106	192	39	219	222	223	223	226	236
Profit before tax	375	620	638	558	569	664	847	494	19	537	622	506	656	766	925
Tax	84	130	130	103	95	125	190	113	-26	96	104	95	100	195	213
Net profit	285	494	501	454	471	536	653	380	45	438	512	409	554	574	711
EPS ₹	7.13	12.15	12.51	11.33	11.76	13.39	16.31	9.45	0.74	10.62	12.39	9.90	13.44	13.76	17.23
Revenue YoY	—	—	—	—	18.9%	12.2%	13.6%	23.9%	-106.2%	23.4%	20.2%	10.4%	—	12.9%	17.3%
Profit YoY	—	—	—	—	65.1%	8.6%	30.4%	-16.2%	-90.5%	-18.3%	-21.7%	7.5%	1135.2%	31.0%	39.1%

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 12 periods

	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
ROE	20.6%	20.5%	21.0%	20.0%	19.3%	11.3%	10.6%	9.0%	9.2%	11.7%	12.6%	12.8%
ROCE	25.8%	25.3%	25.8%	24.2%	25.5%	9.8%	9.9%	9.3%	9.1%	13.1%	13.8%	14.6%
Net margin	17.4%	18.6%	18.4%	19.2%	17.5%	17.8%	15.6%	13.3%	13.1%	13.4%	13.9%	14.6%
EBITDA margin	23.7%	24.5%	24.1%	24.8%	25.4%	24.5%	24.5%	23.7%	23.8%	25.3%	26.0%	26.5%
Debt / equity	0.02	0.02	0.02	0.05	0.05	0.59	0.59	0.55	0.55	0.39	0.39	0.31
Interest coverage	75.70	72.10	64.73	73.10	11.36	10.70	6.15	4.15	4.60	4.63	5.41	6.55
Asset turnover	0.90	0.86	0.89	0.79	0.83	0.33	0.35	0.36	0.37	0.51	0.52	0.53

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 8 periods

	MAR '23	SEP '23	MAR '24	SEP '24	MAR '25	SEP '25	MAR '26	SEP '26
Share capital	40	40	40	40	41	41	41	41
Other equity / reserves	7,395	8,388	9,323	10,525	14,291	15,245	16,259	17,541
Total equity	7,435	8,428	9,363	10,565	14,332	15,286	16,300	17,582
Borrowings	170	179	207	482	8,511	8,369	6,312	5,422
Current liabilities	1,863	2,128	2,120	2,894	5,664	7,098	6,507	5,885
Non-current liabilities	229	336	268	299	7,528	6,187	5,011	5,214
Total assets	9,715	11,098	11,963	13,982	27,760	28,813	28,080	28,954
Property, plant & equipment	2,524	2,942	2,932	2,916	2,908	2,926	2,960	3,037
Capital work-in-progress	493	159	207	224	306	394	655	752
Investments	1,346	2,041	2,568	3,856	2,042	2,947	1,985	1,909
Inventories	1,498	1,534	1,553	1,679	2,094	1,972	2,144	2,345
Receivables	576	1,057	848	1,272	1,538	1,901	1,730	2,179
Cash & equivalents	305	253	382	727	407	328	392	1,114

Cash flow

annual · ₹ crore · line = free cash flow

	FY23	FY24	FY25	FY26
Cash from operations	1,813	2,152	2,413	3,121
Cash from investing	-1,054	-2,082	-12,683	-196
Cash from financing	-740	5	10,290	-2,953
Capex	832	382	520	737
Free cash flow	981	1,770	1,893	2,384
Dividends paid	0	0	0	41

Where the assets sit

Sep '26 · ₹ crore

Fixed assets (PPE)

₹3,037 cr10%

CWIP

₹752 cr3%

Investments

₹1,909 cr7%

Inventories

₹2,345 cr8%

Receivables

₹2,179 cr8%

Cash & equivalents

₹1,114 cr4%

Other assets

₹17,618 cr61%

Peer comparison

largest in Healthcare · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Sun Pharmaceutical Industries Ltd.	4,46,270	1,860.00	40.7	5.00	12.3%
Divi's Laboratories Ltd.	2,73,493	10,320.50	93.5	16.32	17.5%
Torrent Pharmaceuticals Ltd.	1,80,671	4,750.00	85.1	9.83	11.6%
Laurus Labs Ltd.	1,26,430	2,340.00	94.4	20.86	22.1%
Apollo Hospitals Enterprise Ltd.	1,21,453	8,446.00	54.2	11.45	21.1%
Zydus Lifesciences Ltd.	1,19,550	1,197.90	28.6	4.30	15.0%
Dr. Reddy's Laboratories Ltd.	1,14,646	1,373.00	40.9	2.95	7.2%
Cipla Ltd.	1,13,988	1,411.00	39.3	3.22	8.2%
Mankind Pharma Ltd.	1,04,902	2,540.00	46.7	5.97	12.8%
Aurobindo Pharma Ltd.	1,03,572	1,800.00	26.0	2.63	10.1%

StoxGud checklist: Bullish setup · 7/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month+1.6%

6 months+6.9%

1 year+3.9%

3Y CAGR+13.0%

5Y CAGR—

10Y CAGR—

50-day avg₹2,395.52

200-day avg₹2,320.64

RSI (14)72

Compare Mankind Pharma Ltd. with

Zydus Lifesciences vs Mankind Pharma Dr. Reddy's Laboratories vs Mankind Pharma Cipla vs Mankind Pharma Mankind Pharma vs Aurobindo Pharma Mankind Pharma vs Lupin Mankind Pharma vs Max Healthcare Institute

FAQs

What is the share price of Mankind Pharma Ltd.?

Mankind Pharma Ltd. (MANKIND) closed at ₹2,540.00 on NSE on 06 Nov 2026.

What is the market cap of Mankind Pharma Ltd.?

₹1,04,902 crore at the latest close.

What is the P/E ratio of Mankind Pharma Ltd.?

46.7, on trailing-twelve-month earnings from its filings.

How fast is Mankind Pharma Ltd. growing?

Mankind Pharma Ltd.: revenue has compounded at 17.7% a year over three years; net profit at 14.3% a year. Latest-quarter revenue is up 17.3% year on year, profit up 39.1%.

How profitable is Mankind Pharma Ltd.?

On a trailing-twelve-month basis return on equity is 12.8%, return on capital employed 14.6%, operating margin 26.5%, net margin 14.6%.

How much debt does Mankind Pharma Ltd. have?

Mankind Pharma Ltd. is lightly geared: debt to equity is 0.31 with borrowings of ₹5,422 cr against cash of ₹1,114 cr (balance sheet of 2026-09-30). Operating profit covers interest 6.6 times.

Financials parsed from Mankind Pharma Ltd.'s own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from MAR '23, annual from FY23, balance sheet from Mar '23. * = derived (full year or half year minus earlier quarters). Information only, not investment advice.